SMS Pharmaceuticals hits ₹87.61 cr profit as FY26 growth hits target
Revenue climbed 13% to ₹886.87 cr, matching earlier guidance. The board approved a dividend of ₹0.40 per share.
— 2 earlier stories on SMS Pharmaceuticals Ltd. →What's new
- Standalone revenue hit ₹886.87 cr, a 13.3% increase over the previous year.
- Net profit reached ₹87.61 cr, up 28.1% year-on-year.
- Board approved a final dividend of ₹0.40 per share.
Why it matters
Performance matches the prior quarterly guidance exactly. There are no surprises here.
What we're watching
- Margin consistency in upcoming quarterly filings.
- Capital allocation plans following the modest dividend payout.
- Stability of the new auditor's oversight.
The full read
SMS Pharmaceuticals closed FY26 with standalone revenue of ₹886.87 crore, a 13.3% increase from the prior year. Net profit grew by 28.1% to reach ₹87.61 crore. These figures land exactly where the company’s previous quarterly updates suggested they would.
No surprises.
The board approved a modest final dividend of ₹0.40 per share while confirming an unmodified audit opinion. Other changes, such as moving the registered office and appointing new auditors, fall under standard administrative maintenance. The open question is whether the company can maintain this growth pace in FY27 without the tailwinds seen in this reporting cycle. For now, the story remains one of steady, guided execution.